You Have Rights Blog
Smokers or Pfizer: Who Really Needs Chantix to Succeed?
Wednesday, June 04, 2008
The Pfizer public relations machine has been running at full speed lately, ever since widespread reports of suicidal thoughts, aggressive behavior and other serious adverse reactions in users of the pharmaceutical giant’s popular Chantix anti-smoking drug intensified. Chantix users have been experiencing angry, irrational behavior, terrifying dreams and a host of other problems, prompting a non-profit pharmaceutical watch dog group to recently publish a report detailing at least 988 “serious adverse events” relating to the drug filed with FDA during the last 3 months of 2007 – more reports than for any other medication received by FDA during the same…
Digitek Digoxin double thickness pill overdose
Wednesday, May 28, 2008
Mark & Associates, P.C. is currently representing victims of Digitek/digoxin overdose or toxicity due to pills containing twice the normal dose of active ingredient. Digitek, sold under Bertek and UDL labels, and also known as Cardoxin, Lanoxicaps or Lanoxin, was recalled in a Class I nationwide recall announced April 25, 2008. Actavis Totowa LLC (formerly known as Amide Pharmaceutical, Inc.), manufactures Digitek for distributors Mylan Pharmaceuticals Inc. and UDL Laboratories. Digitek is prescribed to treat heart failure and irregular heartbeat (arrhythmia). Tablets were sold with double the thickness as typical tablets, and it is suspected that these pills contained double…
Mark & Associates, P.C. Files Arbitration on Behalf of Bear Stearns Shareholder
Thursday, May 08, 2008
Mark & Associates, P.C. announces that, along with its co-counsel, it has filed an arbitration request with the Financial Industry Regulation Authority "FINRA" (FINRA Dispute Number 08-01137) on behalf of a Bear Stearns shareholder which names The Bear Stearns Companies, Inc. (NYSE: BSC) and its Chief Executive Officer Alan Schwartz as respondents. The Claimant's Statement of Claim alleges that the Claimant suffered significant financial losses when Bear Stearns' stock precipitously declined, which was the result of the respondents breaching their fiduciary responsibility, omitting material facts, and issuing false and misleading statements. Mark & Associates, P.C. anticipates filing additional arbitrations in…
Chinese Manufacturing of Pharmaceuticals Puts Patients at Risk
Tuesday, April 15, 2008
The decision by Baxter International to hire a Chinese pharmaceutical supplier to provide ingredients in the blood thinner heparin has been blamed for dozens of patient deaths and hundreds of injuries worldwide. The controversial move calls into question the growing practice of Western drug manufacturers in relying on Chinese pharmaceutical firms, who often do not follow the same safety standards as American and European firms.Critics contend the cost-cutting move to go overseas and contract with Chinese pharmaceutical plants to produce drug ingredients potentially puts millions of patients unnecessarily at risk of death and serious injury.Halt Chinese Manufacturing Pending Further InvestigationMark…
